Skip to main content

Table 1 Selected average parameters from pressure-volume loop study in vivo assessment of left ventricular function are expressed as mean ± SEM

From: Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response

Variables

Control

Dox

Vitamin E Telmisartan

P value

End-systolic Volume (uL)

43.64 ± 1.23

69.61 ± 2.36

51.34 ± 1.22

<0.05

End-diastolic Volume (uL)

69.61 ± 2.37

85.03 ± 3.53

63.21 ± 1.43

<0.05

End-systolic Pressure (mmHg)

70.57 ± 1.22

56.64 ± 6.76

64.65 ± 1.75

<0.05

End-diastolic Pressure (mmHg)

8.36 ± 1.19

3.42 ± 0.36

7.14 ± 1.54

<0.05

Ejection Fraction (%)

42.34 ± 3.21

17.35 ± 0.57

25.43 ± 1.21

<0.05

Cardiac Output (ml/min)

12.67 ± 1.26

6.03 ± 0.4

7.83 ± 1.17

<0.51

E MAX

21.38 ± 2.36

14.34 ± 1.32

16.43 ± 1.

<0.51

  1. P < 0.05, statistically differences between Dox treated only group and with Vitamin E, and Telmisartan treatment; (n = 8 per group).